Biosimilar mAbs Race: Join It Fast To Stay Ahead Of Competitors By Annemarie Vroom-ten Wolde, Ph.D., contributing editor
Today there's no longer a clear difference between "innovative pharma" and "generic pharma." The difference between the two industrial sectors is rapidly fading away. If you want to enter the biosimilar mAbs field, join it fast to stay ahead of all these possible competitors.
BridgeSourcing: An Alternative To Conventional CMO Outsourcing? By Xcellerex
For many developers of new biologics, outsourcing clinical or commercial manufacturing with a CMO makes good sense. Dozens of capable CMOs offer ready capacity to companies who can't afford the time, capital, or risk involved in building their own biomanufacturing capacity.
New draft guidance available for drug evaluation and research.